Takeda reports late-breaking Phase 3 TAK-921 data in previously treated advanced gastric cancer at ESMO 2026

PUBT · 1d ago
Takeda reports late-breaking Phase 3 TAK-921 data in previously treated advanced gastric cancer at ESMO 2026
  • Takeda flagged late-breaking Phase 3 G-HOPE-001 data for arcotatug tavatecan (TAK-921) in previously treated advanced gastric cancer at ESMO 2026.
  • Final readout could support a Japan regulatory filing for the Claudin 18.2-targeted ADC, which remains investigational.
  • TAK-928 data in immunotherapy-resistant NSCLC and first-line NSCLC will be presented; the asset is a PD-1/alpha-biased IL-2 bispecific fusion protein.
  • Global Phase 3 MarsLight-11 is evaluating TAK-928 versus docetaxel in post-chemotherapy, post-immunotherapy squamous NSCLC; enrollment is ongoing.
  • The program will add a new sub-trial in non-squamous NSCLC, expanding the Phase 3 addressable population.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220930BIZWIRE_USPR_____20260921_BW356638) on September 22, 2026, and is solely responsible for the information contained therein.